Has Rufus Collea, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,213 in general payments to Rufus Collea, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rufus Collea, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rufus Collea, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rufus Collea, MD

Hematology & Oncology · Albany, NYNPI 1205822012

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $950 of the $1,213 with a category attached, or 78.3%. GE HealthCare accounts for 83.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $1,013 and has fallen 81.4% since, to $188 in 2023. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.

$1,213in general payments, 2019–2025

Across 5 payments — averaging $242.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GE HealthCare$1K
Gilead$130
Seagen Inc.$70

What the payments were for

Travel & lodging$95078%
Food & beverage$18115%
Education$827%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GE HealthCare	2	$1,013
Gilead	2	$130
Seagen Inc.	1	$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Trodelvy$118

How this compares

$1,213 in reported general payments places this provider in the 45th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$1,014,612

Medicare patients

403

Services billed

59,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IbrancePalbociclib	31	$443,959
Exemestane	45	$7,715
Letrozole	267	$3,742
Tamoxifen Citrate	80	$1,314
Anastrozole	38	$403
Gabapentin	11	$119

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Albany

Mihir RavalAlbany$767K
Rahul RavillaAlbany$351K
Ira ZackonAlbany$127K
Michael SchusterNew York$1.6M
Charles SawyersNew York$1.6M
Manuel Hidalgo-MedinaNew York$1.4M
Francis ArenaLake Success$1M
Sanjeev JainEast Patchogue$971K
Ross LevineNew York$968K
Perry CookBrooklyn$803K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →